Assets

Lead program: Novel treatment for lung fibrosis

Development of inhaled OM-247 for treatment of fibrotic lung disease, a highly potent compound with low systemic exposure to mitigate toxicity.
 

Follow-up program 1: Novel treatment for osteoarthritis

Explore other options of local delivery using OM-711 by intra-articular delivery for osteoarthritis
 

Follow-up program 2: Novel treatment for cancer

Further develop OM-0815 with increased TI for oral delivery in validated therapeutic areas, - i.e. oncology and also other indications suitable for oral delivery such as kidney fibrosis.